Phase 4 N=488 Valsartan/Amlodipine As Compared to Losartan Treatment in Stage 2 Systolic Hypertension
Stage 2 Systolic Hypertension
Primary: Change in Mean Sitting Systolic Blood Pressure After 6 Weeks — 166.8; 168.5; 135.5; 142.5 mmHg
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=5 HIRREM for Stage 1 Primary Hypertension
Hypertension · Blood Pressure · Cardiovascular Diseases
Primary: Change From Baseline in Blood Pressure, as Measured by an Automated Oscillometric Blood Pressure Device. — -3.00; -6.67; -6.00; -7.67 mmHg
Phase 3 N=261 Obese Hypertension Study (0954-315)
Hypertension
Primary: Mean Change From Baseline in Trough Sitting Systolic Blood Pressure (SiSBP) at Week 8 — -12.1; -6.8 mm Hg
Phase 4 N=433 Nebivolol in Patients With Systolic Stage 2 Hypertension
Hypertension
Primary: Change From Baseline in Mean Seated Systolic Blood Pressure After 6 Weeks of Nebivolol Monotherapy — -18.2; -12.3 mm Hg
Phase 3 N=185 Blood Pressure Lowering Ability and Safety of an Olmesartan and Amlodipine Based Treatment Regimen in Patients With Stage I and Stage II Hypertension
Hypertension
Primary: Change From Baseline in Mean 24-hour Systolic Blood Pressure Measured by Ambulatory Monitoring — -21.4 mm Hg — p=<0.0001
Phase 4 N=664 Efficacy and Safety Study to Evaluate Combination Therapy With Nebivolol and Lisinopril vs. Placebo and Monotherapy in Patients With Stage 2 Diastolic Hypertension
Stage 2 Diastolic Hypertension
Primary: The Change From Baseline in Trough Seated Diastolic Blood Pressure at Week 6. — -8.0; -17.2; -13.3; -12.0 mm HG
N/A N=51 Chiropractic for Hypertension in Patients
Hypertension
Primary: Unadjusted and Adjusted Changes From Baseline in Systolic and Diastolic Blood Pressure at Weeks 1, 3, 6 — -1.2; -5.3; 0.8; -1.7 mmHg
Phase 4 N=860 Aliskiren HCTZ Compared to Amlodipine in Patients With Stage 2 Systolic Hypertension and Diabetes Mellitus
Hypertension · Diabetes Mellitus
Primary: Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) — -28.82; -26.22 mmHg
Phase 4 N=386 Study of the Efficacy and Safety of Aliskiren HCTZ vs Ramipril in Obese Patients (BMI ≥ 30) With Stage 2 Hypertension
Hypertension
Primary: Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP) — 167.0; 168.2; 138.9; 151.6 mm Hg
Phase 4 N=451 8 Weeks Study to Evaluate the Efficacy and Safety of Valsartan in Combination With Aliskiren Compared to Valsartan Alone in Patients With Stage 2 Hypertension
Stage 2 Hypertension
Primary: Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP) at Week 8 — 164.8; 166.2; 142.3; 145.6 mm Hg — p=0.295
Phase 2 N=162 Phase 2b Study of KBP-5074 in Subjects With Uncontrolled Hypertension and Advanced Chronic Kidney Disease
Chronic Kidney Diseases · Hypertension
Primary: Systolic Blood Pressure — 155.8; 154.3; 155.7; 150.4 mmHg
N/A N=56 Mindfulness Based Stress Reduction for High Blood Pressure
Hypertension
Primary: SBP — 130.2; 128.8 mm Hg
Phase 4 N=532 Aliskiren Plus HCTZ Compared to Aliskiren in Metabolic Syndrome Patients With Stage 2 Systolic Hypertension
Hypertension
Primary: Change From Baseline to Week 8 in Mean Sitting Systolic Blood Pressure (msSBP) — -30.38; -20.15 mm Hg
Phase 4 N=332 Blood Pressure Lowering of Aliskiren Hydrochlorothiazide (HCTZ) Versus Amlodipine in Stage 2 Hypertension in African Americans
Hypertension
Primary: Change in Mean Sitting Systolic Blood Pressure (MSSBP) After 8 Weeks of Treatment — 168.2; 168.1; 138.8; 139.1 mm Hg
Phase 2 N=389 Efficacy and Safety of LCZ696 Compared to Placebo in Patients With Essential Hypertension
Hypertension
Primary: Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) — -11.53; -10.98; -12.45; -3.69 mmHg
Phase 4 N=256 Efficacy and Tolerability of an Aliskiren-based Treatment Algorithm in Patients With Mild to Moderate Hypertension
Essential Hypertension ( Mild to Moderate)
Primary: Percentage of Participants (Defined as Estimated Cumulative Control Rate) Reaching Blood Pressure Target in a Stepped Care, Aliskiren-based Regimen — 86.12 Percentage of…
Phase 4 N=451 Blood Pressure Lowering of Aliskiren HCTZ Compared to HCTZ in Stage 2 Systolic Hypertension in Older Population
Hypertension
Primary: Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to Week 4 — -29.6; -22.3 mm Hg
Phase 3 N=688 Efficacy and Safety of the Combination Aliskiren (300 mg) and Hydrochlorothiazide (25mg) to Aliskiren (300mg) Monotherapy in Patients With Staged II Hypertension
Hypertension
Primary: Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to End of Study (Week 12) — -30.01; -20.29 mm Hg
Phase 4 N=888 Telmisartan 80mg Plus Hydrochlorothiazide 25mg First Line in Moderate or Severe Hypertension
Hypertension
Primary: Change From Baseline in Mean Seated Trough Cuff Systolic Blood Pressure (SBP) to Week 7 — -28.5; -37.0 mmHg — p=<0.0001
Phase 2 N=200 Trial on the Safety and Efficacy of MLS-101 in Patients With Uncontrolled Hypertension
Hypertension, Renal
Primary: Change From Baseline in Office-measured Systolic Blood Pressure (SBP) at Study Week 8 Compared to Placebo — -4.10; -11.3; -11.07; -5.63 mmHg
Phase 4 N=1,143 Aliskiren and Valsartan vs Valsartan Alone in Patients With Stage II Systolic Hypertension and Type II Diabetes Mellitus
Hypertension
Primary: Change From Baseline in Mean 24-hour Ambulatory Systolic Blood Pressure (MASBP) at Week 8 — -15.3; -11.5 mmHg
Phase 4 N=412 Aliskiren/Amlodipine/Hydrochlorothiazide (HCTZ) Versus Aliskiren/Amlodipine in US Minority Patients With Stage II Systolic Hypertension
Hypertension
Primary: Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP) at Week 8 — 167.08; 167.41; 130.73; 137.87 mmHg
N/A N=106 Renal Denervation in Patients With Uncontrolled Hypertension (Symplicity HTN-2)
Uncontrolled Hypertension
Primary: Office Systolic Blood Pressure Reduction — -31.7; 0.9 mmHg
Phase 4 N=144 Efficacy and Safety of Olmesartan Medoxomil in Stage 1 and 2 Essential Hypertension
Essential Hypertension
Primary: Number of Patients That Achieved a Blood Pressure Goal of Less Than 130/85 (Olmesartan 20 mg Monotherapy) — 38 Participants
N/A N=203 Interactive Web Program and Health Coaching for Prehypertensive Adults
Weight · Blood Pressure
Primary: Systolic Blood Pressure — 128.99; 131.4; 131.21; 127.45 mm Hg
N/A N=126 Blood Pressure in Dialysis Patients
Hypertension · Renal Failure Chronic Requiring Hemodialysis · Blood Pressure
Primary: Number of Participants Assessed for Intensive (110-140 mm Hg) and Standard (155-165mm Hg) Pre-dialysis Standardized BP Goal — 62; 64 participants
Phase 4 N=233 Candesartan Effect in Second Stage Arterial Hypertension
Stage II Hypertension
Primary: Changes in Mean Sitting DBP From Baseline After 4 Weeks of Therapy — -17.0; -14.1 mmHg
N/A N=574 Targeting of UnControlled Hypertension in Emergency Department
Hypertension · Cardiovascular Diseases · Vascular Diseases
Primary: Mean Systolic Blood Pressure (SBP) Difference at 6 Months Post-intervention Compared to Usual Care. — -9.2; -14.0 mmHg
Phase 4 N=728 The Effects of Moderate vs. Aggressive Treatment With Valsartan + Amlodipine on Patients With Hypertension Uncontrolled by Angiotensin-Receptor Blocker (Herein, ARB) Monotherapy
Hypertension
Primary: Change From Baseline to Week 4 in Mean Sitting Systolic Blood Pressure (MSSBP) — 163.9; 163.3; 140.9; 144.4 mmHg
Phase 3 N=286 MK-0954E Phase III Long-Term Study in Participants With Hypertension (MK-0954E-356)
Hypertension
Primary: Change in Trough Sitting Diastolic Blood Pressure (SiDBP)-Double-Blind Treatment Period — -12.1; -6.2 mmHg — p=<0.001